[ad_1]
Compared to DPP-IV inhibitors, SGLT2 inhibitor empagliflozin was badociated with a 44% reduction in the relative risk of hospitalization for heart failure in people with type 2 diabetes with and without established cardiovascular disease, according to preliminary results of the study EMPRISE announced by Boehringer Ingelheim. and Eli Lilly.
The first results, a realistic badysis of approximately 35,000 people with type 2 diabetes between August 2014 and September 2016, corroborate the data from the EMPA-REG CV survey results history, which demonstrated a 35% reduction in the relative risk of hospitalization for heart failure in people with type 2 diabetes and proven cardiovascular disease compared with placebo. The initial findings of EMPA-REG were presented in September 2015 and communicated by Endocrine today.
"With more than one million hospitalizations for heart failure in the United States each year, it is important to understand whether the relative risk reduction for hospitalization for heart failure seen in the EMPA-REG Outcome trial results in routine clinical care ", Elisabetta Patorno, MD, DrPH, of the Brigham and Women's Hospital Pharmacoepidemiology and Pharmacoeconomics Division and an Assistant Professor of Medicine at Harvard Medical School, in a press release. "These first results of the EMPRISE study show that empagliflozin [Jardiance] is badociated with a reduction in the number of hospitalizations for heart failure and its effect is constant in people with type 2 diabetes with or without a history of cardiovascular disease. "
Companies launched EMPRISE in 2016 to complement the results of the EMPA-REG results test by providing comparative data on the effectiveness, safety, utilization of health care resources and the costs of routine clinical care compared to 5-year DPP-4 inhibitors in people with type 2 diabetes with and without CVD.
"Boehringer Ingelheim and Lilly are committed to helping reduce the burden of cardiovascular disease in people with type 2 diabetes", Thomas Seck, MD, Executive Vice President, Medicine and Regulatory Affairs, Boehringer Ingelheim. "These real-world badyzes build on the clinical results of the EMPA-REG Outcome trial that have paved the way for further research on Jardiance in heart failure, including our studies in the field of heart failure. course. "
The study will evaluate the first five years of use of empagliflozin in the United States between 2014 and 2019. More than 200,000 people with type 2 diabetes from two US commercial health care providers and Medicare should be included at the end of the study. The full results of EMPRISE will be presented in 2019, according to the press release.
"Boehringer Ingelheim and Lilly Diabetes Alliance are committed to building a complete clinical picture of Jardiance across the entire cardiovascular risk continuum of type 2 diabetes", Sherry Martin, MD, The Vice President of Medical Affairs, Lilly Diabetes, said in the release. "Doctors need better options to help their patients avoid hospitalization for heart failure and we are encouraged by the fact that these results from the EMPRISE study complement the cardiovascular outcomes of the EMPA trial. -REG Outcome. We are committed to better understanding if Jardiance could have potential in this area and look forward to sharing the future results of the EMPRISE study. "
The study is part of an academic collaboration between Brigham and Women's hospitals and Boehringer Ingelheim. The security data provided by EMPRISE are not yet available, according to the press release. The results of the IMPRISE will be presented at the scientific sessions of the American Heart Association in Chicago on November 10th. – by Regina Schaffer
Disclosures: Martin is vice president of medical affairs for Lilly Diabetes. Seck is Senior Vice President for Medicine and Regulatory Affairs at Boehringer Ingelheim.
[ad_2]
Source link
